Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Flumatinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Flumatinib is a once-daily tablet for adults with chronic myeloid leukaemia (CML) that carries the Philadelphia chromosome and is still in the chronic phase. It was discovered and is made in China by Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharmaceutical Group, and is sold there as 豪森昕福 (Hansoh Xinfu®). During development it was known as HH-GV678.
China's National Medical Products Administration (NMPA) approved it on 22 November 2019. The Chinese label gives a single use:
The label does not limit this to a particular line of treatment, but the main trial behind the approval enrolled people who had been diagnosed within the previous six months and had not yet taken any tablet of this type. Whether it suits a particular patient is a decision for a haematologist with experience in CML. Our haematology medicines section lists other blood cancer treatments we can help import.
In CML, two chromosomes swap pieces and form the Philadelphia chromosome. This creates a fused gene, BCR-ABL1, which makes an enzyme that is permanently switched on and tells the bone marrow to keep producing white blood cells. This medicine is a tyrosine kinase inhibitor: it blocks the BCR-ABL1 enzyme so the leukaemia cells stop receiving that growth signal. In laboratory tests it switched off the enzyme at very low concentrations, and one of its breakdown products in the body is active as well.
Approval rested on FESTnd (study HS-10096-301, NCT02204644), a phase 3 trial at Chinese centres. It randomised 394 adults with newly diagnosed chronic-phase CML to this tablet at 600 mg once a day or to a comparison medicine, an older standard tablet, for 12 months.
The label also reports that a major molecular response came sooner, at a median of 8.5 months against 11.3 months.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Who should not take it: anyone allergic to the active substance or any ingredient in the tablet. In the main trial, 41.8% of patients had at least one side effect of grade 3 or higher, so regular check-ups are part of treatment.
Other points: it is broken down mainly by the liver enzyme CYP3A4, so strong blockers or boosters of that enzyme (found among some antibiotics, antifungals, HIV medicines and epilepsy medicines) should be avoided or used only under medical advice. There is no information on use in pregnancy or breastfeeding; women who could become pregnant should use effective contraception, and it is given in pregnancy only if the benefit clearly outweighs the risk to the baby. Safety in people under 18 has not been established, and dizziness or tiredness may affect driving. Caution is also advised in people with glaucoma, heart failure risk or past kidney failure.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets are imported for one named patient, by the patient or a hospital, under India's rules for importing unapproved medicines. Please keep these ready:
Once we have checked a valid prescription and, where required, the import permit has been issued.
No. CDSCO has not approved it, so Indian pharmacies do not stock it. It is approved only in China; the US FDA and the European Medicines Agency have not approved it.
A patient can still receive it through the Named Patient Program (NPP), which allows a medicine without Indian registration to be imported for one person on a doctor's prescription. We also help families access other China-approved leukaemia tablets, such as lisaftoclax for chronic lymphocytic leukaemia.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The label asks for the tablets to be kept sealed below 30°C, so the boxes travel unopened under temperature-controlled shipping that avoids heat exposure on the way. At the standard dose a patient needs three 200 mg tablets a day, roughly three 30-tablet boxes a month, and we plan shipments so a new supply arrives before the current one runs out. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Because CML treatment runs for years, most families want a dependable monthly supply. Once the haematologist's prescription and import papers are in order, the tablets can be sent to the cities below and many smaller towns.
Haematology clinics in Delhi see many newly diagnosed CML patients, and dispatch from New Delhi means the tablets usually reach them quickly.
A haematologist in Mumbai can send the BCR-ABL1 report and prescription, and we deliver to the patient's home or hospital pharmacy.
Families in Bangalore get a written quote for a month's supply first, so they can plan before anything is ordered.
For patients in Chennai, we line up each delivery with the blood-count reviews that are frequent in the first two months.
Leukaemia teams in Hyderabad can request the tablets for a named patient once the chronic phase is confirmed.
CML patients in Kolkata and the north-eastern states can have each monthly box couriered from Delhi, with the dispatch details shared by message.
We help families in Pune keep a steady monthly supply, since this daily tablet works best when doses are not missed.
Doctors in Ahmedabad can share the diagnosis and treatment history, and we explain which papers are still pending.
Patients followed up at hospitals in Vellore can have the boxes sent to the hospital to match their clinic visits.
Haematologists in Chandigarh treating patients from Punjab, Haryana and Himachal can ask us to send the tablets ahead of each review visit.
In Lucknow, a family can choose delivery at home or to the leukaemia clinic where the PCR tests are done.
For Kerala, monthly parcels go to Kochi, Thrissur or another town close to the patient.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message